[1]方向南,王瑒,郭莉,等.血清非磷酸化未羧化基质Gla蛋白与绝经后骨质疏松症的关系[J].国际内分泌代谢杂志,2021,41(03):164-167，190.[doi:10.3760/cma.j.cn121383-20200615-06039]
　Fang Xiangnan,Wang Yang,Guo Li,et al.Relationship between serum desphospho-uncarboxylated matrix Gla protein and postmenopausal osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(03):164-167，190.[doi:10.3760/cma.j.cn121383-20200615-06039]
点击复制

血清非磷酸化未羧化基质Gla蛋白与绝经后骨质疏松症的关系()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年03期
页码:
164-167，190
栏目:
论著
出版日期:
2021-05-20

文章信息/Info

Title:
Relationship between serum desphospho-uncarboxylated matrix Gla protein and postmenopausal osteoporosis
作者:
方向南1; 王瑒1; 郭莉1; 洪世华1; 谢满2; 吕维名1; 胡承3
1赣南医学院第一附属医院内分泌科,赣州 341000; 2赣南医学院第一附属医院健康体检中心,赣州 341000; 3上海交通大学附属第六人民医院上海市糖尿病研究所 200000
Author(s):
Fang Xiangnan1;  Wang Yang1;  Guo Li1;  Hong Shihua1;  Xie Man2;  Lyu Weiming1;  Hu Cheng3.
1Department of Endocrinology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China; 2Department of Health Management Center, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, Chi
关键词:
非磷酸化未羧化基质Gla蛋白;  绝经后骨质疏松症;  骨密度;  骨代谢指标
Keywords:
Desphospho-uncarboxylated matrix Gla protein;  Postmenopausal osteoporosis;  Bone mineral density;  Bone metabolism biomarkers
DOI:
10.3760/cma.j.cn121383-20200615-06039
摘要:
目的 探讨血清非磷酸化未羧化基质Gla蛋白(dp-ucMGP)与绝经后骨质疏松症(PMOP)及骨代谢指标的关系。方法 选取2017年12月至2019年12月在赣南医学院第一附属医院健康体检中心就诊或内分泌代谢科住院的绝经后女性共248名作为研究对象。采用双能X线吸收骨密度仪(DXA)测定骨密度(BMD)。根据BMD将研究对象分为骨量正常组(n=86)、骨量减少组(n=64)和PMOP组(n=98)。采用酶联免疫吸附法(ELISA)检测血清dp-ucMGP水平。并检测血钙、血磷、血β胶原降解产物Ⅰ型胶原羧基端肽(β-CTX)和Ⅰ型前胶原N-端前肽(PINP)等骨代谢指标。结果 3组间年龄、绝经年限、体重指数(BMI)、骨钙素、β-CTX、PINP和dp-ucMGP差异有统计学意义(P<0.05)。Pearson相关分析表明血清dp-ucMGP与年龄(r=0.254,P=0.042)、绝经年限(r=0.343, P=0.036)、β-CTX(r=0.023, P=0.025)呈正相关,与BMI(r=-0.169,P=0.041)、腰椎BMD(r=-0.176,P=0.031)、股骨颈BMD(r=-0.234, P=0.025)和骨钙素(r=-0.176, P=0.034)呈负相关。二元logistic回归分析提示年龄(OR=1.164, P=0.024)、绝经年限(OR=1.151, P=0.031)、β-CTX(OR=1.122, P=0.037)和dp-ucMGP(OR=1.244, P=0.033)为PMOP的危险因素,校正年龄和绝经年限后,dp-ucMGP(OR=1.237,P=0.045)仍为PMOP的危险因素。结论 血清dp-ucMGP可能成为PMOP的潜在生物标志物。
Abstract:
Objective To investigate the relationship between serum desphospho-uncarboxylated matrix Gla protein(dp-ucMGP)and bone metabolic biomarkers in postmenopausal osteoporosis(PMOP)patients.Methods A total of 248 postmenopausal women who attended the Department of Health Management Center, or the Department of Endocrinology and Metabolism in the First Affiliated Hospital of Gannan Medical College from December 2017 to December 2019 were enrolled. Bone mineral density(BMD)was measured by dual-energy X-ray absorptiometry(DXA). Based on BMD, the participants were divided into normal bone mass group(n=86), osteopenia group(n=64)and PMOP group(n=98). Serum dp-ucMGP was measured by enzyme-linked immunosorbent assay(ELISA). Bone metabolic biomarkers such as calcium, phosphorus, β-crosslinking C-telopeptide of type Ⅰ collagen(β-CTX)and procollagen type Ⅰ N-terminal propeptide(PINP)were also measured.Results The differences of age, years since menopause, BMI, osteocalcin, β-CTX, PINP, and dp-ucMGP among three groups were significant(P<0.05). Pearson correlation analysis indicated that serum dp-ucMGP was positively correlated with age(r=0.254, P=0.042), years since menopause(r=0.343, P=0.036)and β-CTX(r=0.023, P=0.025), and negatively correlated with BMI(r=-0.169, P=0.041), lumbar spine BMD(r=-0.176, P=0.031), femoral neck BMD(r=-0.234, P=0.025)and osteocalcin(r=-0.176, P=0.034). Binary logistic regression analysis suggested that age(OR=1.164, P=0.024), years since menopause(OR=1.151, P=0.031), β-CTX(OR=1.122, P=0.037)and dp-ucMGP(OR=1.244, P=0.033)were risk factors for PMOP. After adjusted for age and years since menopause, dp-ucMGP(OR=1.237, P=0.045)was also an risk factor for PMOP.Conclusion Serum dp-ucMGP may be a potential biomarker of PMOP.

参考文献/References:

[1] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-443.DOI:10.3969/j.issn.1674-2591.2017.05.002.
[2] 王涛,马信龙.骨质疏松发病机制研究进展[J]. 国际内分泌代谢杂志,2014,34(2):99-102.DOI:10.3760/cma.j.issn.1673-4157.2014.02.008.
[3] Cranenburg EC,Koos R,Schurgers LJ,et al. Characterisation and potential diagnostic value of circulating matrix Gla protein(MGP)species[J]. Thromb Haemost,2010,104(4):811-822.DOI:10.1160/th09-11-0786.
[4] Cannata-Andia JB,Roman-Garcia P,Hruska K. The connections between vascular calcification and bone health[J]. Nephrol Dial Transplant,2011,26(11):3429-3436.DOI:10.1093/ndt/gfr591.
[5] Naves M,Rodriguez-Garcia M,Diaz-Lopez JB,et al. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures[J]. Osteoporos Int,2008,19(8):1161-1166.DOI:10.1007/s00198-007-0539-1.
[6] Mayer OJ,Seidlerová J,Bruthans J,et al. Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease[J]. Atherosclerosis,2014,235(1):162-168.DOI:10.1016/j.atherosclerosis.2014.04.027.
[7] Mayer O Jr,Seidlerová J,Wohlfahrt P,et al. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population[J]. J Hum Hypertens,2016,30(7):418-423.DOI:10.1038/jhh.2015.55.
[8] Mayer OJ,Bruthans J,Seidlerová J,et al. The coincidence of low vitamin K status and high expression of growth differentiation factor 15 may indicate increased mortality risk in stable coronary heart disease patients[J]. Nutr Metab Cardiovasc Dis,2021,31(2):540-551.DOI:10.1016/j.numecd.2020.09.015.
[9] Evenepoel P,Claes K,Meijers B,et al. Poor vitamin K status is associated with low bone mineral density and increased fracture risk in end-stage renal disease[J]. J Bone Miner Res,2019,34(2):262-269.DOI:10.1002/jbmr.3608.
[10] Price PA,Urist MR,Otawara Y. Matrix Gla protein,a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone[J]. Biochem Biophys Res Commun,1983,117(3):765-771.DOI:10.1016/0006-291x(83)91663-7.
[11] Luo G,Ducy P,McKee MD,et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein[J]. Nature,1997,386(6620):78-81.DOI:10.1038/386078a0.
[12] Dalmeijer GW,van der Schouw YT,Magdeleyns E,et al. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein[J]. Atherosclerosis,2012,225(2):397-402.DOI:10.1016/j.atherosclerosis.2012.09.019.
[13] Zhang Y,Zhao L,Wang N,et al. Unexpected role of matrix Gla protein in osteoclasts:Inhibiting osteoclast differentiation and bone resorption[J]. Mol Cell Biol,2019,39(12):e00012-e00019. DOI:10.1128/MCB.00012-19.
[14] 赖晓阳,方向南,陈雪英,等.四种骨质疏松治疗药物对原代SD大鼠成骨细胞MGP表达的[J].中华内分泌代谢杂志,2012,28(12):956-961.DOI:10.3760/cma.j.issn.1000-6699.2012.12.003.
[15] 陈雪英,姜醒华,赖晓阳,等.雌二醇对去卵巢大鼠基质GLA蛋白表达的影响[J]. 中华妇产科杂志,2012,47(11):833-838.DOI:10.3760/cma.j.issn.0529-567x.2012.11.008.
[16] Vilovic M,Dogas Z,Ticinovic KT,et al. Bone metabolism parameters and inactive matrix Gla protein in patients with obstructive sleep apnea[J].Sleep,2020,43(3):zsz243.DOI:10.1093/sleep/zsz243.
[17] Tsukamoto K,Orimo H,Hosoi T,et al. Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women[J]. J Bone Miner Metab,2000,18(1):27-30.DOI:10.1007/s007740050006.
[18] 周广文,向楠,沈霖,等.血清基质Gla蛋白与绝经后骨质疏松症的相关性[J]. 中华骨质疏松和骨矿盐疾病杂志,2015,8(4):294-299.DOI:10.3969/j.issn.1674-2591.2015.04.002.
[19] Moore A E,Kim E,Dulnoan D,et al. Serum vitamin K(1)(phylloquinone)is associated with fracture risk and hip strength in post-menopausal osteoporosis:A cross-sectional study[J].Bone,2020,141:115630.DOI:10.1016/j.bone.2020.115630.

备注/Memo

备注/Memo:
通信作者:胡承,Email:alfredhc@sjtu.edu.cn 基金项目:赣州市科技局计划(GZ2019ZSF054)
更新日期/Last Update: 2021-05-20